Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 13 of 13 results for temozolomide

  1. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.

    Technology appraisal guidance
    Published
    27 June 2007
    View recommendations

    Sections for TA121

  2. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

    Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

    Technology appraisal guidance
    Last updated
    3 March 2016
    View recommendations

    Sections for TA23

  3. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  4. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

    NICE guideline
    Last updated
    29 January 2021
    View recommendations

    Sections for NG99

  5. Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)

    Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.

    Technology appraisal guidance
    Published
    29 May 2024
    View recommendations

    Sections for TA977

  6. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

    Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    22 October 2014
    View recommendations

    Sections for TA321

  7. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]

    Awaiting development Reference number: GID-TA11741 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Managing glioma: management of IDH wildtype grade II glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in patients with IDH wildtype grade II glioma?

    wildtype grade II glioma:- Does the addition of concurrent and adjuvant temozolomide to radiotherapy improve overall survival in...

    Research recommendation
    Published
    11 December 2018

  10. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  11. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over (TA1147)

    Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.

    Technology appraisal guidance
    Published
    29 April 2026
    View recommendations

    Sections for TA1147

  12. Enzalutamide for the treatment of hormone refractory prostate cancer TA316

    Discontinued Reference number: GID-TA10267

    Technology appraisal guidance
    Discontinued

  13. ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

    In development Reference number: GID-TA10489 Expected publication date: TBC

    Technology appraisal guidance
    In development